Envestnet Asset Management
CRSP icon

Envestnet Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Envestnet Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.82M Sell
70,081
-12,125
-15% -$639K ﹤0.01% 2666
2026
Q1 		$3.91M Buy
82,206
+25,634
+45% +$1.35M ﹤0.01% 2510
2025
Q4 		$2.97M Sell
56,572
-13,817
-20% -$827K ﹤0.01% 2539
2025
Q3 		$4.56M Buy
70,389
+2,447
+4% +$140K ﹤0.01% 2311
2025
Q2 		$3.3M Sell
67,942
-116
-0.2% -$4.49K ﹤0.01% 2489
2025
Q1 		$2.32M Buy
68,058
+12,025
+21% +$510K ﹤0.01% 2626
2024
Q4 		$2.21M Buy
56,033
+1,256
+2% +$59.3K ﹤0.01% 2631
2024
Q3 		$2.57M Buy
54,777
+14,131
+35% +$717K ﹤0.01% 2502
2024
Q2 		$2.2M Sell
40,646
-671
-2% -$38.8K ﹤0.01% 2544
2024
Q1 		$2.82M Buy
41,317
+1,930
+5% +$138K ﹤0.01% 2359
2023
Q4 		$2.47M Buy
39,387
+10,767
+38% +$595K ﹤0.01% 2335
2023
Q3 		$1.3M Buy
28,620
+10,607
+59% +$548K ﹤0.01% 2619
2023
Q2 		$1.01M Sell
18,013
-1,527
-8% -$86.6K ﹤0.01% 2738
2023
Q1 		$884K Sell
19,540
-4,945
-20% -$240K ﹤0.01% 2759
2022
Q4 		$995K Buy
24,485
+2,643
+12% +$140K ﹤0.01% 2648
2022
Q3 		$1.43M Buy
21,842
+14
+0.1% +$1.01K ﹤0.01% 2291
2022
Q2 		$1.33M Buy
21,828
+2,739
+14% +$161K ﹤0.01% 2379
2022
Q1 		$1.2M Buy
19,089
+2,668
+16% +$168K ﹤0.01% 2543
2021
Q4 		$1.24M Buy
16,421
+566
+4% +$49.4K ﹤0.01% 2480
2021
Q3 		$1.77M Sell
15,855
-5,736
-27% -$720K ﹤0.01% 2164
2021
Q2 		$3.5M Buy
21,591
+5,656
+35% +$688K ﹤0.01% 1725
2021
Q1 		$1.94M Buy
15,935
+6,457
+68% +$975K ﹤0.01% 1954
2020
Q4 		$1.45M Buy
9,478
+5,452
+135% +$644K ﹤0.01% 1967
2020
Q3 		$337K Buy
+4,026
New +$357K ﹤0.01% 2682

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Envestnet Asset Management's CRSP Position: Q2 2026 in Review

Envestnet Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 15% in Q2 2026, selling an estimated $639K and leaving 70,081 shares worth $3.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2666.

Envestnet Asset Management first reported a position in CRSP in Q3 2020 and has held it in 24 quarters since. The position peaked at $4.56M in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Envestnet Asset Management held 70,081 shares of CRISPR Therapeutics worth $3.82M as of Q2 2026.
  • Envestnet Asset Management sold 12,125 CRISPR Therapeutics shares in Q2 2026, an estimated $639K.
  • CRISPR Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #2666 holding.
  • Envestnet Asset Management first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Envestnet Asset Management's CRISPR Therapeutics position peaked at $4.56M in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.